Patents by Inventor David Michel Adrien Taddei

David Michel Adrien Taddei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11453662
    Abstract: A process for producing a compound of the following formula (I) which process comprises: (a) treating a compound of the following formula (5) with a compound of the following formula (6) to generate an intermediate compound of the following formula (7); (b) treating a compound of formula (7) as defined above with a compound of the following formula (8); and (c) recovering a compound of formula (I) as defined above. The compound of formula (I) is a promising modulator of p300/CBP activity that has potential utility in treating cancers, including prostate cancer, haematological cancers, bladder cancer and lung cancer.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 27, 2022
    Assignee: CELLCENTRIC LTD
    Inventors: Paul Baguley, Donald Alan Gilbert, Gareth Harbottle, Colin Lindley, John Paul Madeley, James Vaughan Morey, David Michel Adrien Taddei, Jonathan Trevorrow, David Wood
  • Patent number: 11377443
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: July 5, 2022
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Publication number: 20210163463
    Abstract: A process for producing a compound of the following formula (I) which process comprises: (a) treating a compound of the following formula (5) with a compound of the following formula (6) to generate an intermediate compound of the following formula (7); (b) treating a compound of formula (7) as defined above with a compound of the following formula (8); and (c) recovering a compound of formula (I) as defined above. The compound of formula (I) is a promising modulator of p300/CBP activity that has potential utility in treating cancers, including prostate cancer, haematological cancers, bladder cancer and lung cancer.
    Type: Application
    Filed: April 18, 2019
    Publication date: June 3, 2021
    Inventors: Paul BAGULEY, Donald Alan GILBERT, Gareth HARBOTTLE, Colin LINDLEY, John Paul MADELEY, James Vaughan MOREY, David Michel Adrien TADDEI, Jonathan TREVORROW, David WOOD
  • Publication number: 20200407349
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Application
    Filed: May 14, 2020
    Publication date: December 31, 2020
    Inventors: Neil Anthony PEGG, Stuart Thomas ONIONS, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Richard James BROWN, Don SMYTH, Gareth HARBOTTLE
  • Patent number: 10696666
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: June 30, 2020
    Assignee: CELLCENTRIC LIMITED
    Inventors: Neil Anthony Pegg, Stuart Thomas Onions, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Richard James Brown, Don Smyth, Gareth Harbottle
  • Patent number: 10647704
    Abstract: A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 12, 2020
    Assignee: CELLCENTRIC LTD
    Inventors: Neil Anthony Pegg, David Michel Adrien Taddei, Jonathan Shannon, Silvia Paoletta, Ting Qin, Gareth Harbottle
  • Publication number: 20190375740
    Abstract: A compound which is an arylimidazolyl isoxazole of formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Application
    Filed: October 18, 2017
    Publication date: December 12, 2019
    Inventors: Neil Anthony PEGG, Stuart Thomas ONIONS, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Richard James BROWN, Don SMYTH, Gareth HARBOTTLE
  • Patent number: 10428065
    Abstract: A compound which is an isoxazolyl imidazopyridine of formula (I): wherein: R0 and R, which are the same or different, are each H or C alkyl; R9? and R9?, which are the same or different, are each H or F; X is -(alk)n-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R? and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; R2 and R2?, which are the same or different, are each H or C1-6 alkyl; or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3?, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: October 1, 2019
    Assignee: CELLCENTRIC LTD
    Inventors: Neil Anthony Pegg, David Michel Adrien Taddei, Richard Brown
  • Publication number: 20190263788
    Abstract: A compound which is a benzimidazole of formula (I): wherein X is a 5-membered heteroaryl group selected from the following: or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Application
    Filed: October 18, 2017
    Publication date: August 29, 2019
    Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Jonathan SHANNON, Silvia PAOLETTA, Ting QIN, Gareth HARBOTTLE
  • Patent number: 10118920
    Abstract: A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R?; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2?, which are the same or different, are each H or C1-6 alkyl, or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: November 6, 2018
    Assignee: CELLCENTRIC LTD
    Inventors: Neil Anthony Pegg, David Michel Adrien Taddei, Stuart Thomas Onions, Eric Sing Yuen Tse, Richard James Brown, David Kenneth Mycock, David Cousin, Anil Patel
  • Publication number: 20180127402
    Abstract: A compound which is a benzimidazolyl isoxazole of formula (I): wherein: R0 and R, which are the same or different, are each H or C1-6 alkyl; R9, R9 and R9, which are the same or different, are each H or F; X is -(alkn-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R?; a 4- to 6-membered, C-linked heterocyclic group which is unsubstituted or substituted; and an N-linked spiro group of the following formula: R2 and R2?, which are the same or different, are each H or C1-6 alkyl, or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered, N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer, particularly prostate cancer.
    Type: Application
    Filed: April 20, 2016
    Publication date: May 10, 2018
    Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Stuart Thomas ONIONS, Eric Sing Yuen TSE, Richard James BROWN, David Kenneth MYCOCK, David COUSIN, Anil PATEL
  • Publication number: 20180105519
    Abstract: A compound which is an isoxazolyl imidazopyridine of formula (I): wherein: R0 and R, which are the same or different, are each H or C alkyl; R9? and R9?, which are the same or different, are each H or F; X is -(alk)n-, -alk-C(?O)—NR—, -alk-NR—C(?O)— or -alk-C(?O)—; R1 is selected from —S(?O)2R? and a 4- to 7-membered heterocyclic group which is unsubstituted or substituted; R2 and R2?, which are the same or different, are each H or C1-6 alkyl; or R2 and R2? form, together with the C atom to which they are attached, a C3-6 cycloalkyl group; R3 and R3?, which are the same or different, are each H, C1-6 alkyl, OH or F; R4 is phenyl or a 5- to 12-membered N-containing heteroaryl group and is unsubstituted or substituted; alk is C1-6 alkylene; R? is C1-6 alkyl; and n is 0 or 1; or a pharmaceutically acceptable salt thereof. The compound has activity in modulating the activity of p300 and/or CBP and is used to treat cancer.
    Type: Application
    Filed: April 20, 2016
    Publication date: April 19, 2018
    Inventors: Neil Anthony PEGG, David Michel Adrien TADDEI, Richard BROWN
  • Publication number: 20170334919
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 23, 2017
    Applicant: RESPIVERT LTD.
    Inventors: Rudy Laurent Maria Broeckx, Alex Herman Copmans, Alun John Smith, David Michel Adrien Taddei, Stuart Thomas Onions
  • Patent number: 9745306
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: August 29, 2017
    Assignee: Respivert Limited
    Inventors: Rudy Laurent Maria Broeckx, Alex Herman Copmans, Alun John Smith, David Michel Adrien Taddei, Stuart Thomas Onions
  • Patent number: 9556184
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: January 31, 2017
    Assignee: Respivert, Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • Patent number: 9447028
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: September 20, 2016
    Assignee: King's College London
    Inventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
  • Publication number: 20160090389
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: December 4, 2015
    Publication date: March 31, 2016
    Applicant: Respivert Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx
  • Publication number: 20160039747
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-amido-aryl compounds of the following formula (for convenience, collectively referred to herein as “AAA compounds”), which, inter alia, are (selective) retinoic acid receptor ? (RAR?) agonists. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) activate RAR?, and in the treatment of diseases and conditions that are mediated by RAR?, that are ameliorated by the activation of RAR?, etc., including cognitive disorders, memory impairment, memory deficit, senile dementia, Alzheimer's disease, early stage Alzheimer's disease, intermediate stage Alzheimer's disease, late stage Alzheimer's disease, cognitive impairment, and mild cognitive impairment.
    Type: Application
    Filed: October 9, 2015
    Publication date: February 11, 2016
    Inventors: Jonathan Patrick Thomas Corcoran, Sarkis Barret Kalindjian, Alan David Borthwick, David Reginald Adams, Jane Theresa Brown, David Michel Adrien Taddei, Jason John Shiers
  • Publication number: 20160039826
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 11, 2016
    Inventors: Rudy Laurent Maria Broeckx, Alex Herman Copmans, Alun John Smith, David Michel Adrien Taddei, Stuart Thomas Onions
  • Patent number: 9227977
    Abstract: The present invention relates inter alia to a compound of formula (I) and to compositions comprising the same and to the use of the compounds and to compositions of the compounds in treatment, for example in the treatment of inflammatory diseases, in particular respiratory inflammatory disease. The invention also extends to methods of making the said compounds.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 5, 2016
    Assignee: Respivert Ltd.
    Inventors: David Michel Adrien Taddei, Stuart Thomas Onions, Alun John Smith, Alex Herman Copmans, Rudy Laurent Maria Broeckx